Drug Approval | February 03, 2022
USFDA approves first generic of Restasis
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Previously, the use of the drug was limited to patients requiring hospitalization
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
The approval is for Cytomegalovirus, a type of Herpes virus
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Subscribe To Our Newsletter & Stay Updated
